文献速递临床试验与 GCP

先天性膈疝新生儿神经调节辅助通气随机交叉试验研究方案:NAN-C研究

Study protocol for a randomised cross-over trial of Neurally adjusted ventilatory Assist for Neonates with Congenital diaphragmatic hernias: the NAN-C study.
PubMed 文献 · Trials · 2024-01-20

NAN-C是一项双中心随机交叉试验,旨在比较先天性膈疝(CDH)婴儿术后神经调节辅助通气(NAVA)与辅助控制通气(ACV)的效果。符合条件的婴儿先进入通气支持耐受试验(VSTT)评估随机化适宜性,临床稳定者按1:1随机先后接受NAVA或ACV各4小时,测量氧合指数、呼吸严重程度评分和累积镇静药物使用。这是首个比较NAVA与ACV的前瞻性交叉试验。

要点

  • NAVA根据膈肌电信号成比例提供通气压力,临床医生可调节支持水平以降低患者呼吸做功。
  • 既往CDH婴儿病例系列显示NAVA可能降低氧合指数和平均气道压。
  • 本试验为首项比较CDH婴儿术后NAVA与ACV的前瞻性随机交叉试验,主要测量氧合指数、呼吸严重程度评分和累积镇静药物使用。

核心结论

  • 据作者所知,这是首个比较NAVA与ACV的前瞻性交叉试验,旨在评估CDH婴儿术后NAVA与ACV的通气支持效果。

研究设计与样本

  • 双中心随机交叉试验,纳入先天性膈疝(CDH)婴儿,术后比较NAVA与辅助控制通气(ACV)。
  • 符合条件婴儿先进入通气支持耐受试验(VSTT)评估随机化适宜性,临床稳定者按1:1随机先后接受NAVA或ACV各4小时。
  • 试验已在ClinicalTrials.gov前瞻性注册,注册号NCT05839340,注册时间为2023年5月。

主要发现

  • 既往CDH婴儿病例系列显示NAVA可能降低氧合指数和平均气道压。
  • 回顾性研究比较NAVA与ACV显示该通气模式可能改善呼吸参数并使新生儿获益。
  • 本试验将测量氧合指数、呼吸严重程度评分和累积镇静药物使用。

临床怎么用

  • 作者认为NAVA可能改善CDH新生儿的呼吸参数并使其获益,但需本前瞻性交叉试验进一步验证。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neurally adjusted ventilatory assist (NAVA) is a mode of mechanical ventilation that delivers oxygen pressures in proportion to electrical signals of the diaphragm. The proportional assistance can be adjusted by the clinician to reduce the patient's work of breathing. Several case series of infants with congenital diaphragmatic hernias (CDH) have shown that NAVA may reduce oxygenation index and mean airway pressures. To date, no clinical trial has compared NAVA to standard methods of mechanical ventilation for babies with CDH. METHODS: The aim of this dual-centre randomised cross-over trial is to compare post-operative NAVA with assist control ventilation (ACV) for infants with CDH. If eligible, infants will be enrolled for a ventilatory support tolerance trial (VSTT) to assess their suitability for randomisation. If clinically stable during the VSTT, infants will be randomised to receive either NAVA or ACV first in a 1:1 ratio for a 4-h period. The oxygenation index, respiratory severity score and cumulative sedative medication use will be measured. DISCUSSION: Retrospective studies comparing NAVA to ACV in neonates with congenital diaphragmatic hernia have shown the ventilatory mode may improve respiratory parameters and benefit neonates. To our knowledge, this is the first prospective cross-over trial comparing NAVA to ACV. TRIAL REGISTRATION: NAN-C was prospectively registered on ClinicalTrials.gov NCT05839340 Registered on May 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Poole G, Harris C, Shetty S, et al. Study protocol for a randomised cross-over trial of Neurally adjusted ventilatory Assist for Neonates with Congenital diaphragmatic hernias: the NAN-C study. Trials. 2024. PMID: 38245741. doi:10.1186/s13063-023-07874-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。